# IBI3009

Source: https://onco.cc/drugs/ibi3009/  
OnCo record `ibi3009` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IBI3009 is an experimental antibody-drug conjugate for small cell lung cancer, aimed at the protein DLL3. Innovent Biologics licensed it to Roche in January 2025, and it is in a first phase 1 trial.

## Summary

IBI3009 is an antibody-drug conjugate that targets DLL3 and carries a payload from Innovent Biologics' topoisomerase 1 inhibitor platform; the registry describes it as a monoclonal antibody-camptothecin derivative conjugate. Innovent announced a collaboration and exclusive licence with Roche on 2 January 2025, by which time IBI3009 had approval to start trials in Australia, China and the United States and the first patient had been dosed in December 2024. The phase 1 trial (NCT06613009), sponsored by Innovent, is enrolling people with unresectable, metastatic or extensive-stage small cell lung cancer. No results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; deal-asset
- Modality: Antibody-drug conjugate (DLL3, topoisomerase I inhibitor payload)
- Mechanism: An antibody that recognises DLL3, a protein found on small cell lung cancer and other neuroendocrine tumours but rarely on normal tissue, carries a camptothecin-type topoisomerase I inhibitor into the cancer cell.

## Sources

- Innovent and Roche licence announcement, January 2025 (Drug Discovery Online copy): https://www.drugdiscoveryonline.com/doc/innovent-enters-into-exclusive-global-license-roche-for-novel-dll-antibody-drug-conjugate-0001
- ClinicalTrials.gov: IBI3009 phase 1 (NCT06613009): https://clinicaltrials.gov/study/NCT06613009

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/), [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct06613009/)

---
JSON: https://onco.cc/api/v1/entities/ibi3009.json